Figure 4From: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseTime course of appearance of IgM and IgG antibodies against PEG-uricase, and of plasma uricase activity, in 'early elimination' subjects 002, 011, and 013. Subject 002 received 4 mg, and subjects 011 and 013 each received 12 mg, of PEG-modified recombinant mammalian urate oxidase (PEG-uricase).Back to article page